Autopsy report · NCT04052763

FFR-CT to Detect the Absence of Hemodynamically Significant Lesions in Patients With High-risk Acute Coronary Syndrome

“Slow enrolment during the COVID pandemics”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 4 months before it stopped.
• 164 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Centre Hospitalier Universitaire Vaudois

Sponsor type

University, hospital or other

Conditions

Acute Coronary Syndrome

Interventions

FFR-CT; FFRangio™

Participants

164

Sites

1

Countries

Switzerland

Trials that died the same way

• Intraocular Pressure and Optic Nerve Sheath Diameter Changes in Laparoscopic Cholecystectomies
  “As a result of COVID-19 pandemics” (69% match in meaning)
• Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.
  “Enrollment slower than anticipated and interrupted by COVID-19 pandemic” (68% match in meaning)
• Pharmacokinetics and Safety of Moxifloxacin
  “slow enrolment of patients and new insights” (67% match in meaning)
• Resting Energy Expenditure in Patients With OHS Treated With Long-term NIV
  “COVID pandemic” (66% match in meaning)
• Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced Pneumatic Compression Device (PCD)
  “Due to slow enrollment during COVID” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.